A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• DNA damage response is crucial for genome integrity and cancer drug efficacy.
• Cisplatin resistance often arises from DNA repair mechanisms like nucleotide excision repair (NER).

Purpose of the Study:

• To design and evaluate a novel platinum(IV) prodrug that inhibits NER and overcomes cisplatin resistance.
• To investigate a dual-action strategy targeting DNA damage and repair pathways simultaneously.

Main Methods:

• Rational design of a platinum(IV) anticancer prodrug.
• Evaluation of cellular uptake and DNA-damaging capacity.
• Assessment of NER inhibition and apoptotic response.
• Testing against cisplatin-resistant human cancer cells.

Main Results:

• The Pt(IV) prodrug efficiently enters cancer cells and induces DNA damage.
• The prodrug significantly inhibits nucleotide excision repair (NER).
• It demonstrates potent activity against cisplatin-resistant cells, with up to 88-fold increased growth inhibition compared to cisplatin.
• The prodrug outperforms a combination of cisplatin and an NER inhibitor.

Conclusions:

• Targeting downstream pathways, specifically NER, after platinum-induced DNA damage is a viable strategy to combat cisplatin resistance.
• This dual-action prodrug offers a promising therapeutic approach for resistant cancers.
• Inhibiting NER alongside inducing DNA damage enhances the antitumor effect.